Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Clostridioides difficile Infection (rCDI).
Khanna S, Sims M, Louie TJ, Fischer M, LaPlante K, Allegretti J, Hasson BR, Fonte AT, McChalicher C, Ege DS, Bryant JA, Straub TJ, Ford CB, Henn MR, Wang EEL, von Moltke L, Wilcox MH. Khanna S, et al. Among authors: mcchalicher c. Antibiotics (Basel). 2022 Sep 10;11(9):1234. doi: 10.3390/antibiotics11091234. Antibiotics (Basel). 2022. PMID: 36140013 Free PMC article. Review.
SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial.
McGovern BH, Ford CB, Henn MR, Pardi DS, Khanna S, Hohmann EL, O'Brien EJ, Desjardins CA, Bernardo P, Wortman JR, Lombardo MJ, Litcofsky KD, Winkler JA, McChalicher CWJ, Li SS, Tomlinson AD, Nandakumar M, Cook DN, Pomerantz RJ, Auninš JG, Trucksis M. McGovern BH, et al. Among authors: mcchalicher cwj. Clin Infect Dis. 2021 Jun 15;72(12):2132-2140. doi: 10.1093/cid/ciaa387. Clin Infect Dis. 2021. PMID: 32255488 Free PMC article. Clinical Trial.
SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection.
Feuerstadt P, Louie TJ, Lashner B, Wang EEL, Diao L, Bryant JA, Sims M, Kraft CS, Cohen SH, Berenson CS, Korman LY, Ford CB, Litcofsky KD, Lombardo MJ, Wortman JR, Wu H, Auniņš JG, McChalicher CWJ, Winkler JA, McGovern BH, Trucksis M, Henn MR, von Moltke L. Feuerstadt P, et al. Among authors: mcchalicher cwj. N Engl J Med. 2022 Jan 20;386(3):220-229. doi: 10.1056/NEJMoa2106516. N Engl J Med. 2022. PMID: 35045228 Clinical Trial.
Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity.
Glitza IC, Seo YD, Spencer CN, Wortman JR, Burton EM, Alayli FA, Loo CP, Gautam S, Damania A, Densmore J, Fairchild J, Cabanski CR, Wong MC, Peterson CB, Weiner B, Hicks N, Aunins J, McChalicher C, Walsh E, Tetzlaff MT, Hamid O, Ott PA, Boland GM, Sullivan RJ, Grossmann KF, Ajami NJ, LaVallee T, Henn MR, Tawbi HA, Wargo JA. Glitza IC, et al. Among authors: mcchalicher c. Cancer Discov. 2024 Jul 1;14(7):1161-1175. doi: 10.1158/2159-8290.CD-24-0066. Cancer Discov. 2024. PMID: 38588588 Free PMC article. Clinical Trial.
End-to-end donor screening and manufacturing controls: complementary quality-based strategies to minimize patient risk for donor-derived microbiome therapeutics.
Goldsmith J, Tomkovich S, Auniņš JG, McGovern BH, Mahoney JC, Hasson BR, McChalicher CWJ, Ege DS. Goldsmith J, et al. Among authors: mcchalicher cwj. Gut Microbes. 2024 Jan-Dec;16(1):2402550. doi: 10.1080/19490976.2024.2402550. Epub 2024 Sep 18. Gut Microbes. 2024. PMID: 39292598 Free PMC article. Review.
Bacterial synthesis of PHA block copolymers.
Pederson EN, McChalicher CW, Srienc F. Pederson EN, et al. Among authors: mcchalicher cw. Biomacromolecules. 2006 Jun;7(6):1904-11. doi: 10.1021/bm0510101. Biomacromolecules. 2006. PMID: 16768413